RPS23P10: A Promising Drug Target / Biomarker (G100419471)

Target Name: RPS23P10

NCBI ID: G100419471

RPS23P10

Other Name(s): ribosomal protein S23 pseudogene 10 | Ribosomal protein S23 pseudogene 10

RPS23P10: A Promising Drug Target / Biomarker

The RPS23P10 gene is located on chromosome 16 and encodes for the protein RPS23P10, which is a key regulator of mitochondrial fusion and fusion-dependent processes. Mutations in the RPS23P10 gene have been linked to a variety of cellular and biological processes, including skeletal and cardiovascular diseases, neurodegenerative diseases, and diseases associated with aging. As a result, the RPS23P10 gene has become a focus of interest in recent years, with researchers investigating its potential as a drug target or biomarker.

Drug Target Potential

The RPS23P10 gene has been identified as a potential drug target due to its involvement in a variety of cellular processes that are crucial for human health. One of the key functions of RPS23P10 is its role in regulating mitochondrial fusion, which is the process by which mitochondria fuse with each other to form a single mitochondrial organ. This process is essential for energy production and has been implicated in a number of cellular processes, including metabolism, cell death, and aging.

In addition to its role in regulating mitochondrial fusion, RPS23P10 has also been shown to play a key role in the regulation of cellular stress responses. When cells are exposed to stress, RPS23P10 helps to ensure that they are able to adapt and recover from the stress, protecting the cell from damage and death. This function of RPS23P10 makes it an attractive target for drugs that are designed to promote cellular stress tolerance and survival.

Biomarker Potential

The RPS23P10 gene has also been identified as a potential biomarker for a variety of diseases. For example, studies have shown that RPS23P10 is downregulated in a variety of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This suggests that RPS23P10 may be a useful biomarker for these diseases, as potential therapeutic approaches may involve targeting the RPS23P10 gene to promote neurodegeneration.

In addition to its potential as a drug target or biomarker, the RPS23P10 gene is also of interest to researchers who are studying the role of mitochondria in aging and age-related diseases. As telomeres are the protective caps at the end of chromosomes that help to ensure the stability of cellular processes, age-related telomere shortening (ATS) is a hallmark of aging. Studies have shown that RPS23P10 is involved in the regulation of telomere dynamics, which suggests that it may be a useful target for therapies aimed at extending telomeres and reducing the risk of age-related diseases.

Conclusion

In conclusion, the RPS23P10 gene has been identified as a potential drug target and biomarker, with research suggesting that it plays a key role in a variety of cellular and biological processes that are essential for human health. Further studies are needed to fully understand the role of RPS23P10 in these processes and to determine its potential as a therapeutic approach. As research continues to progress, the RPS23P10 gene is likely to become a focus of interest for researchers and clinicians who are seeking new and effective treatments for a variety of diseases.

Protein Name: Ribosomal Protein S23 Pseudogene 10

The "RPS23P10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS23P10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets